Evidence map›Paper›PMID 37387602›Full record

ArticleCancer medicine2023

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.

Xiaomi Li, Xiaoyan Ding, Mei Liu, Jingyan Wang, Wei Sun, Ying Teng, Yawen Xu, Hongxiao Wu, Wendong Li, Lin Zhou and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaomi LiDepartment of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-6386-6640
Xiaoyan DingDepartment of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Mei LiuDepartment of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Jingyan WangDepartment of Interventional Radiology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Wei SunDepartment of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Ying TengDepartment of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yawen XuDepartment of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Hongxiao WuDepartment of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Wendong LiDepartment of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Lin ZhouDepartment of Interventional Radiology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Jinglong ChenDepartment of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsHepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) predicts a poor prognosis. The aim of the present study was to evaluate the efficacy and safety of using lenvatinib and camrelizumab combined with transarterial chemoembolization (TACE) to treat HCC with PVTT.

methodsThis was a single-arm, open-label, multicenter, and prospective study. Eligible patients with advanced HCC accompanied by PVTT were enrolled to receive TACE combined with lenvatinib and camrelizumab. The primary endpoint was progression-free survival (PFS), while the secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.

resultsBetween April 2020 and April 2022, 69 patients were successfully enrolled. With a median follow-up time of 17.3 months, the median age of the patient cohort was 57 years (range: 49-64 years). According to modified Response Evaluation Criteria in Solid Tumors, the ORR was 26.1% (18 partial responses [PRs]) and the DCR was 78.3% (18 PRs, 36 stable diseases [SDs]). The median PFS (mPFS) and median OS (mOS) were 9.3 and 18.2 months, respectively. And tumor number >3 was identified as an adverse risk factor for both PFS and OS. The most common adverse events across all grades included fatigue (50.7%), hypertension (46.4%), and diarrhea (43.5%). Twenty-four patients (34.8%) experienced Grade 3 toxicity that was relieved by dose adjustment and symptomatic treatment. No treatment-related deaths occurred.

conclusionsTACE combined with lenvatinib and camrelizumab is a well-tolerated modality treatment with promising efficacy for advanced HCC with PVTT.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsThrombosisAntibodies, Monoclonal, HumanizedHumansMiddle AgedPhenylurea CompoundsPortal VeinProspective StudiesQuinolinesRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedcamrelizumablenvatinibPhenylurea CompoundsQuinolinescamrelizumabhepatocellular carcinomalenvatinibportal vein tumor thrombustransarterial chemoembolization

Identifiers

PMID37387602
PMCPMC10501288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.